JP2002502885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002502885A5 JP2002502885A5 JP2000531196A JP2000531196A JP2002502885A5 JP 2002502885 A5 JP2002502885 A5 JP 2002502885A5 JP 2000531196 A JP2000531196 A JP 2000531196A JP 2000531196 A JP2000531196 A JP 2000531196A JP 2002502885 A5 JP2002502885 A5 JP 2002502885A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vector
- histamine
- artery
- angiogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2177398A | 1998-02-11 | 1998-02-11 | |
| US09/021,773 | 1998-02-11 | ||
| PCT/US1999/002702 WO1999040945A2 (en) | 1998-02-11 | 1999-02-09 | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002502885A JP2002502885A (ja) | 2002-01-29 |
| JP2002502885A5 true JP2002502885A5 (https=) | 2006-03-30 |
Family
ID=21806073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531196A Pending JP2002502885A (ja) | 1998-02-11 | 1999-02-09 | 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1695719A1 (https=) |
| JP (1) | JP2002502885A (https=) |
| KR (1) | KR20010015915A (https=) |
| CN (2) | CN101186928A (https=) |
| AU (1) | AU2663799A (https=) |
| CA (1) | CA2320302A1 (https=) |
| EA (1) | EA019099B1 (https=) |
| IL (1) | IL137765A0 (https=) |
| NZ (1) | NZ545047A (https=) |
| WO (1) | WO1999040945A2 (https=) |
| ZA (1) | ZA991102B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034208A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| WO2000024415A2 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| EP1255822A2 (en) | 1999-12-27 | 2002-11-13 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
| WO2002002148A2 (en) * | 2000-06-30 | 2002-01-10 | Collateral Therapeutics, Inc. | Dual recombinant gene therapy compositions and methods of use |
| JP2005052001A (ja) * | 2001-07-05 | 2005-03-03 | Takara Bio Inc | 遺伝子治療剤 |
| DE602006017071D1 (de) | 2005-01-25 | 2010-11-04 | Five Prime Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten |
| GB2437893A (en) * | 2006-07-25 | 2007-11-07 | Celladon Corp | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
| US8157760B2 (en) | 2007-07-18 | 2012-04-17 | Silk Road Medical, Inc. | Methods and systems for establishing retrograde carotid arterial blood flow |
| WO2009105135A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
| US20130096500A1 (en) * | 2011-07-07 | 2013-04-18 | Gabor Rubanyi | Nucleic acid based cardiovascular therapeutics |
| US20140296769A1 (en) * | 2013-03-28 | 2014-10-02 | Silk Road Medical, Inc. | Methods and Systems for Establishing Retrograde Carotid Arterial Blood Flow |
| WO2019089385A1 (en) | 2017-11-02 | 2019-05-09 | Silk Road Medical, Inc. | Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA001616B1 (ru) * | 1995-02-28 | 2001-06-25 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ | Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре |
| US5869230A (en) * | 1995-03-30 | 1999-02-09 | Beth Israel Hospital Association | Gene transfer into the kidney |
| WO1999017807A1 (en) * | 1997-10-08 | 1999-04-15 | Cobra Therapeutics Ltd. | Use of a vasoactive compound in the enhancement of gene delivery |
| US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
-
1999
- 1999-02-09 JP JP2000531196A patent/JP2002502885A/ja active Pending
- 1999-02-09 EP EP05026675A patent/EP1695719A1/en not_active Withdrawn
- 1999-02-09 CA CA002320302A patent/CA2320302A1/en not_active Abandoned
- 1999-02-09 AU AU26637/99A patent/AU2663799A/en not_active Abandoned
- 1999-02-09 CN CNA2007101808364A patent/CN101186928A/zh active Pending
- 1999-02-09 EP EP99906814A patent/EP1053025A2/en not_active Withdrawn
- 1999-02-09 KR KR1020007008781A patent/KR20010015915A/ko not_active Ceased
- 1999-02-09 EA EA200000828A patent/EA019099B1/ru not_active IP Right Cessation
- 1999-02-09 IL IL13776599A patent/IL137765A0/xx unknown
- 1999-02-09 CN CNB998049425A patent/CN100350979C/zh not_active Expired - Fee Related
- 1999-02-09 WO PCT/US1999/002702 patent/WO1999040945A2/en not_active Ceased
- 1999-02-09 NZ NZ545047A patent/NZ545047A/en not_active IP Right Cessation
- 1999-02-11 ZA ZA9901102A patent/ZA991102B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8178493B2 (en) | Method for inducing angiogenesis in a heart of a patient | |
| JP5231587B2 (ja) | Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防 | |
| US8455453B2 (en) | Use of VEGF-D gene to prevent restenosis | |
| JP2002502885A5 (https=) | ||
| JP2003513942A5 (https=) | ||
| WO2000021548A2 (en) | Angiogenically effective unit dose of fgf and method of administering | |
| Stegmann | FGF-1: a human growth factor in the induction of neoangiogenesis | |
| Melillo et al. | Gene therapy for collateral vessel development | |
| US6329348B1 (en) | Method of inducing angiogenesis | |
| CA2289600A1 (en) | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes | |
| Gonçalves | Angiogenic growth factors: potential new treatment for acute myocardial infarction? | |
| US7709450B2 (en) | Stimulation of vascularization with VEGF-B-186 | |
| Stegmann | New approaches to coronary heart disease: induction of neovascularisation by growth factors | |
| Webster | Therapeutic angiogenesis: a case for targeted, regulated gene delivery | |
| Bashir et al. | Angiogenic gene therapy: pre-clinical studies and phase I clinical data | |
| Jejurikar et al. | Induction of Angiogenesis by Lidocaine and Basic Fibroblast Growth Factor: A Model forin VivoRetroviral-Mediated Gene Therapy | |
| EP1568375A1 (en) | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis | |
| Stegmann et al. | Combined Local Angiogenesis and Surgical Revascularization for | |
| US9149507B2 (en) | Method of treating coronary artery disease by administering FGF-9 | |
| Miraliakbari et al. | Therapeutic angiogenesis: appropriate for clinical use? | |
| Asahara et al. | Molecular and cellular cardiology: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery | |
| MG-O | ACKNOWLEDGEMENTS: FUNDING STATEMENT | |
| AU2002326311A1 (en) | Stimulation of vascularization with VEGF-B |